3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
21
Lung Neoplasms
10
Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
6
Skin Neoplasms
6
Prostatic Neoplasms
5
Neoplasm Metastasis
5
Melanoma
5
Head and Neck Neoplasms
5
Urinary Bladder Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Renal Cell
4
Carcinoma, Merkel Cell
4
Breast Neoplasms
4
Sarcoma
3
Pancreatic Neoplasms
3
Mycosis Fungoides
3
Carcinoma, Squamous Cell
3
Carcinoma, Hepatocellular
3
Carcinoma, Basal Cell
3
Adenocarcinoma
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Rectal Neoplasms
2
Oropharyngeal Neoplasms
2
Mouth Neoplasms
2
Mesothelioma, Malignant
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Interventions
Sorafenib
42
Bevacizumab
26
Oxaliplatin
21
Radiosurgery
19
Gemcitabine
17
Fluorouracil
15
Hepatectomy
13
lenvatinib
12
Radiofrequency Ablation
11
Nivolumab
11
Cisplatin
11
Radiotherapy
10
Doxorubicin
10
Capecitabine
10
durvalumab
9
Leucovorin
9
Blood Specimen Collection
9
atezolizumab
8
Liver Transplantation
8
Everolimus
7
Electroporation
7
pembrolizumab
6
camrelizumab
6
Sunitinib
6
Immunohistochemistry
6
Cryosurgery
6
Carboplatin
6
tremelimumab
5
sintilimab
5
apatinib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Liver Neoplasms
×
cemiplimab
×
Clear all
NCT06923761
2026-01-28
EMITT-1
Grey Wolf Therapeutics
Phase 1/2
Recruiting
300 enrolled